Antiproliferative effect of silybin on gynaecological malignancies: Synergism with cisplatin and doxorubicin

European Journal of Cancer

Volumn 32, Issue 5, 1996, Pages 877-882

  Scambia, G ^a   De Vincenzo, R ^a   Ranelletti, F O ^a   Panici, P Benedetti ^a   Ferrandina, G ^a   D'Agostino, G ^a   Fattorossi, A ^a   Bombardelli, E ^b   Mancuso, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b INDENA S P A   (Italy)

Author keywords

Ovarian and breast cancer; Silybin; Synergism with CDDP and DOX

Indexed keywords

CISPLATIN; DOXORUBICIN; ESTROGEN RECEPTOR; FLAVONOID; QUERCETIN; SILIBININ;

ARTICLE; BREAST CANCER; CELL CYCLE PHASE; CONTROLLED STUDY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; SILYMARIN; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0030005527     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00011-1     Document Type: Article

References (26)

1. Bosisio E, Benelli C, Pirola O. Effect of the flavanolignans of Silybum marianum on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res 1992, 25, 147-154.
2. Abad MJ, Bermejo P, Villar A, Valverde S. Anti-inflammatory activity in two flavonoids from "Tanace microphillum". J Nat Prod 1993, 56, 1164-1167.
3. Verma A, Johnson JA, Gould MN, Tanner MA. Inhibition of 7, 12-dimethylbenz (a) anthracene and N-nitrosomethylurea induced rat mammary cancer by dietary flavonol quercetin. Cancer Res 1988, 48, 5754-5758.
4. Cassady JM. Natural products as a source of potential cancer chemotherapeutic and chemopreventive agents. J Nat Prod 1990, 53, 23-41.
5. Larocca LM, Piantelli M, Leone G, et al. Type II oestrogen binding sites in acute lymphoid and non-lymphoid leukemias. Growth inhibitory effect of oestrogens and flavonoids. Br J Haematol 1990, 75, 489-495.
6. Markaverich BM, Roberts RR, Alejandro MA, Johnnan GA, Middledich BS, Clark GM. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J Steroid Biochem 1988, 30, 71-78.
7. Scambia G, Ranelletti FO, Benedetti-Panici P, et al. Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells. Br J Cancer 1990, 62, 942-946.
8. Scambia G, Ranelletti FO, Benedetti-Panici P, et al. Quercetin inhibits the growth of a multidrug-resistant estrogen receptor negative MCF-7 human breast cancer cell line expressing type II estrogen binding sites. Cancer Chemother Pharmacol 1991, 28, 255-258.
9. Scambia G, Ranelletti FO, Benedetti Panici P, et al. Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum (II). Gynecol Oncol 1992, 45, 13-19.
10. Hofman J, Fiebig HH, Winterhalter BR, Berger DP, Grunicke H. Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum by quercetin. Int J Cancer 1990, 45, 536-539.
11. Gugler R, Lochik M, Dengler MJ. Disposition of Quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 1975, 9, 229-235.
12. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of liver. J Hepatol 1989, 9, 105-113.
13. Moscarella S, Giusti A, Marra F, et al. Therapeutic and antilipoperoxidant effects of Silybin-phosphatidylcholine complex in chronic liver disease: preliminary results. Curr Ther Res 1993, 53, 98-102.
14. Sica G, Dell'Acqua G, Iacopino F, et al. Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural β-interferon. Urol Res 1994, 22, 36-38.
15. Berenbaum MC. Criteria for analyzing interaction between biologically active agents. Adv Cancer Res 1981, 25, 269-335.
16. Hamburger AW, Salmon SE. Primary bioassay of human stem cell. Science 1977, 197, 461-463.
17. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. AnalBiochem 1976, 72, 248-254.
18. Markaverich BM, Adams NR, Roberts RR, Alejandro M, Clark JH. Cytosol Type II sites in the rat uterus: interaction with an endogenous ligand. J Steroid Biochem 1987, 28, 599-608.
19. Scatcard G. The attraction of protein for small molecules and ions. Ann NYAcad Sci 1949, 51, 660-672.
20. Syne JS, Markaverich BM, Clark JH, Panko WB. Estrogen binding sites in the nucleus of normal and malignant human tissue: characteristics of the multiple nuclear binding sites. Cancer Res 1982, 42, 4449-4454.
21. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 1976, 62, 315-317.
22. Yugarani T, Tan BKH, Teh M, Das NP. Effects of poliphenolic natural products on the lipid profiles of rat fed high fat diet. Lipids 1992, 27, 171-176.
23. Agarwal R, Katiyar SK, Lundgren DW, Mukhtar H. Inhibitory effect of silymarin, an antihepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis 1994, 15, 1099-1103.
24. Fraval HNA, Roberts JJ. G1-phase Chinese hamster V79-379A cells are inherently more sensitive to platinum bound to their DNA than mid S phase or asynchronously treated cells. Biochem Pharmacol 1979, 28, 1575-1580.
25. Scambia G, Ranelletti FO, Benedetti-Panici P, et al. Quercetin potentiates the effect of Adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994, 34, 459-464.
26. De Vincenzo R, Scambia G, Benedetti Panici P, et al. Effect of synthetic and naturally occurring chalchones on ovarian cancer cell growth: structure-activity relationship. Anticancer Drug Des 1995, 10, 481-490.